Discovery, preclinical and early clinical development of eCF506/NXP900: the first total SRC inhibitor

Información

Fecha: 12/02/2025
Hora 10:15
Lugar: Sala Legado Dolores Elósegui (2ª planta)
Conferenciante Asier Unciti-Broceta
Procedencia Edinburgh Cancer Research, Institute of Genetics and Cancer, CRUK Scotland Centre, University of Edinburgh
Invitado por Óscar Llorca, Macromolecular Complexes in DNA Damage Response Group, Structural Biology Programme
Entrada libre hasta completar aforo